Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells

Natalia Escacena, Elena Quesada-Hernández, Vivian Capilla-Gonzalez, Bernat Soria, Abdelkrim Hmadcha, Natalia Escacena, Elena Quesada-Hernández, Vivian Capilla-Gonzalez, Bernat Soria, Abdelkrim Hmadcha

Abstract

Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multidifferentiation, as well as by their anti-inflammatory, antiproliferative, immunomodulatory, trophic, and proangiogenic properties. Various diseases have been treated by MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Moreover, autologous MSCs can be affected by the disease status of patients, compromising their use. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of the host (patient) medical conditions on MSCs is important for assuring the safety and efficacy of cell-based therapies. This review provides relevant information regarding factors to consider for the clinical application of MSCs.

References

    1. Jiang Y., Jahagirdar B. N., Reinhardt R. L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418(6893):41–49. doi: 10.1038/nature00870.
    1. da Silva Meirelles L., Chagastelles P. C., Nardi N. B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of Cell Science. 2006;119(11):2204–2213. doi: 10.1242/jcs.02932.
    1. Caplan A. I. All MSCs are pericytes? Cell Stem Cell. 2008;3(3):229–230. doi: 10.1016/j.stem.2008.08.008.
    1. Prockop D. J., Oh J. Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14–20. doi: 10.1038/mt.2011.211.
    1. Petrie R. J., Doyle A. D., Yamada K. M. Random versus directionally persistent cell migration. Nature Reviews Molecular Cell Biology. 2009;10(8):538–549. doi: 10.1038/nrm2729.
    1. Hoogduijn M. J., Popp F., Verbeek R., et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. International Immunopharmacology. 2010;10(12):1496–1500. doi: 10.1016/j.intimp.2010.06.019.
    1. da Silva Meirelles L., Fontes A. M., Covas D. T., Caplan A. I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine and Growth Factor Reviews. 2009;20(5-6):419–427. doi: 10.1016/j.cytogfr.2009.10.002.
    1. Shrestha C., Zhao L., Chen K., He H., Mo Z. Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media. International Journal of Endocrinology. 2013;2013:10. doi: 10.1155/2013/592454.592454
    1. Burlacu A., Grigorescu G., Rosca A.-M., Preda M. B., Simionescu M. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells and Development. 2013;22(4):643–653. doi: 10.1089/scd.2012.0273.
    1. Friedenstein A. J., Deriglasova U. F., Kulagina N. N., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Experimental Hematology. 1974;2(2):83–92.
    1. Zuk P. A., Zhu M., Mizuno H., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering. 2001;7(2):211–228. doi: 10.1089/107632701300062859.
    1. Erices A., Conget P., Minguell J. J. Mesenchymal progenitor cells in human umbilical cord blood. British Journal of Haematology. 2000;109(1):235–242. doi: 10.1046/j.1365-2141.2000.01986.x.
    1. Gronthos S., Mankani M., Brahim J., Robey P. G., Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(25):13625–13630. doi: 10.1073/pnas.240309797.
    1. Díaz-Prado S., Muiños-López E., Hermida-Gómez T., et al. Multilineage differentiation potential of cells isolated from the human amniotic membrane. Journal of Cellular Biochemistry. 2010;111(4):846–857. doi: 10.1002/jcb.22769.
    1. Pittenger M. F. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147.
    1. Owen M., Friedenstein A. J. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Foundation Symposium. 1988;136:42–60.
    1. Caplan A. I. Mesenchymal stem cells. Journal of Orthopaedic Research. 1991;9(5):641–650. doi: 10.1002/jor.1100090504.
    1. Dennis J. E., Merriam A., Awadallah A., Yoo J. U., Johnstone B., Caplan A. I. A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. Journal of Bone and Mineral Research. 1999;14(5):700–709. doi: 10.1359/jbmr.1999.14.5.700.
    1. Bianco P., Robey P. G. Marrow stromal stem cells. Journal of Clinical Investigation. 2000;105(12):1663–1668. doi: 10.1172/jci10413.
    1. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., Verfaillie C. M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Experimental Hematology. 2002;30(8):896–904. doi: 10.1016/s0301-472x(02)00869-x.
    1. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905.
    1. Caplan A. I. What's in a name? Tissue Engineering, Part A. 2010;16(8):2415–2417. doi: 10.1089/ten.tea.2010.0216.
    1. de Ugarte D. A., Alfonso Z., Zuk P. A., et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunology Letters. 2003;89(2-3):267–270. doi: 10.1016/s0165-2478(03)00108-1.
    1. Krampera M., Franchini M., Pizzolo G., Aprili G. Mesenchymal stem cells: from biology to clinical use. Blood Transfusion. 2007;5(3):120–129. doi: 10.2450/2007.0029-07.
    1. Sakaguchi Y., Sekiya I., Yagishita K., Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis & Rheumatism. 2005;52(8):2521–2529. doi: 10.1002/art.21212.
    1. Capra E., Beretta R., Parazzi V., et al. Changes in the proteomic profile of adipose tissue-derived mesenchymal stem cells during passages. Proteome Science. 2012;10(1, article 46) doi: 10.1186/1477-5956-10-46.
    1. Wagner W., Bork S., Lepperdinger G., et al. How to track cellular aging of mesenchymal stromal cells? Aging. 2010;2(4):224–230.
    1. Tarte K., Gaillard J., Lataillade J.-J., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2010;115(8):1549–1553. doi: 10.1182/blood-2009-05-219907.
    1. Caplan A. I. Why are MSCs therapeutic? New data: new insight. The Journal of Pathology. 2009;217(2):318–324. doi: 10.1002/path.2469.
    1. Stenderup K., Justesen J., Clausen C., Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919–926. doi: 10.1016/j.bone.2003.07.005.
    1. Schäfer R., Knauf U., Zweyer M., et al. Age dependence of the human skeletal muscle stem cell in forming muscle tissue. Artificial Organs. 2006;30(3):130–140. doi: 10.1111/j.1525-1594.2006.00199.x.
    1. McAuley D. F., Curley G. F., Hamid U. I., et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. The American Journal of Physiology—Lung Cellular and Molecular Physiology. 2014;306(9):L809–L815. doi: 10.1152/ajplung.00358.2013.
    1. Liang J., Zhang H., Hua B., et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Annals of the Rheumatic Diseases. 2010;69(8):1423–1429.
    1. Prockop D. J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71–74. doi: 10.1126/science.276.5309.71.
    1. Bruder S. P., Jaiswal N., Haynesworth S. E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. Journal of Cellular Biochemistry. 1997;64(2):278–294.
    1. Woodbury D., Reynolds K., Black I. B. Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. Journal of Neuroscience Research. 2002;69(6):908–917. doi: 10.1002/jnr.10365.
    1. Kern S., Eichler H., Stoeve J., Klüter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294–1301. doi: 10.1634/stemcells.2005-0342.
    1. Horwitz E. M., Gordon P. L., Koo W. K. K., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(13):8932–8937. doi: 10.1073/pnas.132252399.
    1. Nicola M. D., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838–3843. doi: 10.1182/blood.v99.10.3838.
    1. Raffaghello L., Bianchi G., Bertolotto M., et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26(1):151–162. doi: 10.1634/stemcells.2007-0416.
    1. Hmadcha A., Domínguez-Bendala J., Wakeman J., Arredouani M., Soria B. The immune boundaries for stem cell based therapies: problems and prospective solutions. Journal of Cellular and Molecular Medicine. 2009;13(8):1464–1475. doi: 10.1111/j.1582-4934.2009.00837.x.
    1. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003;5(6):485–489. doi: 10.1080/14653240310003611.
    1. Conget P. A., Minguell J. J. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. Journal of Cellular Physiology. 1999;181(1):67–73. doi: 10.1002/(sici)1097-4652(199910)181:1x003C;67::aid-jcp7x0003e;;2-c.
    1. Glennie S., Soeiro I., Dyson P. J., Lam E. W.-F., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105(7):2821–2827. doi: 10.1182/blood-2004-09-3696.
    1. Benvenuto F., Ferrari S., Gerdoni E., et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells. 2007;25(7):1753–1760. doi: 10.1634/stemcells.2007-0068.
    1. Stagg J., Pommey S., Eliopoulos N., Galipeau J. Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood. 2006;107(6):2570–2577. doi: 10.1182/blood-2005-07-2793.
    1. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726–736. doi: 10.1038/nri2395.
    1. Menard C., Pacelli L., Bassi G., et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells and Development. 2013;22(12):1789–1801. doi: 10.1089/scd.2012.0594.
    1. Krampera M., Cosmi L., Angeli R., et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24(2):386–398. doi: 10.1634/stemcells.2005-0008.
    1. Sivanathan K. N., Gronthos S., Rojas-Canales D., Thierry B., Coates P. T. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Reviews and Reports. 2014;10(3):351–375. doi: 10.1007/s12015-014-9495-2.
    1. Najar M., Raicevic G., Boufker H. I., et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cellular Immunology. 2010;264(2):171–179. doi: 10.1016/j.cellimm.2010.06.006.
    1. Yoo K. H., Jang I. K., Lee M. W., et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cellular Immunology. 2009;259(2):150–156. doi: 10.1016/j.cellimm.2009.06.010.
    1. Ricciardi M., Malpeli G., Bifari F., et al. Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow. PLoS ONE. 2012;7(5) doi: 10.1371/journal.pone.0035639.e35639
    1. Krampera M. Mesenchymal stromal cell licensing: a multistep process. Leukemia. 2011;25(9):1408–1414. doi: 10.1038/leu.2011.108.
    1. Wegmeyer H., Bröske A.-M., Leddin M., et al. Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells and Development. 2013;22(19):2606–2618. doi: 10.1089/scd.2013.0016.
    1. Hunt J. S., Petroff M. G., McIntire R. H., Ober C. HLA-G and immune tolerance in pregnancy. The FASEB Journal. 2005;19(7):681–693. doi: 10.1096/fj.04-2078rev.
    1. Lee J. M., Jung J., Lee H.-J., et al. Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. International Immunopharmacology. 2012;13(2):219–224. doi: 10.1016/j.intimp.2012.03.024.
    1. Fazekasova H., Lechler R., Langford K., Lombardi G. Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs. Journal of Tissue Engineering and Regenerative Medicine. 2011;5(9):684–694. doi: 10.1002/term.362.
    1. Melief S. M., Zwaginga J. J., Fibbe W. E., Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Translational Medicine. 2013;2(6):455–463. doi: 10.5966/sctm.2012-0184.
    1. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology. 2002;30(1):42–48. doi: 10.1016/S0301-472X(01)00769-X.
    1. Ren G., Su J., Zhang L., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27(8):1954–1962. doi: 10.1002/stem.118.
    1. Krampera M., Galipeau J., Shi Y., Tarte K., Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells-the international society for cellular therapy (ISCT) working proposal. Cytotherapy. 2013;15(9):1054–1061. doi: 10.1016/j.jcyt.2013.02.010.
    1. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755–1761. doi: 10.1182/blood-2005-04-1496.
    1. Gordon D., Pavlovska G., Glover C. P., Uney J. B., Wraith D., Scolding N. J. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neuroscience Letters. 2008;448(1):71–73. doi: 10.1016/j.neulet.2008.10.040.
    1. Rafei M., Birman E., Forner K., Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Molecular Therapy. 2009;17(10):1799–1803. doi: 10.1038/mt.2009.157.
    1. Constantin G., Marconi S., Rossi B., et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009;27(10):2624–2635. doi: 10.1002/stem.194.
    1. Bai L., Lennon D. P., Eaton V., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009;57(11):1192–1203. doi: 10.1002/glia.20841.
    1. Zhang J., Li Y., Chen J., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Experimental Neurology. 2005;195(1):16–26. doi: 10.1016/j.expneurol.2005.03.018.
    1. Sun L., Wang D., Liang J., et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis and Rheumatism. 2010;62(8):2467–2475. doi: 10.1002/art.27548.
    1. González M. A., González-Rey E., Rico L., Büscher D., Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis and Rheumatism. 2009;60(4):1006–1019. doi: 10.1002/art.24405.
    1. Jurewicz M., Yang S., Augello A., et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010;59(12):3139–3147. doi: 10.2337/db10-0542.
    1. Fiorina P., Jurewicz M., Augello A., et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. The Journal of Immunology. 2009;183(2):993–1004. doi: 10.4049/jimmunol.0900803.
    1. Lee R. H., Seo M. J., Reger R. L., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(46):17438–17443. doi: 10.1073/pnas.0608249103.
    1. Sudres M., Norol F., Trenado A., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. The Journal of Immunology. 2006;176(12):7761–7767. doi: 10.4049/jimmunol.176.12.7761.
    1. Tisato V., Naresh K., Girdlestone J., Navarrete C., Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21(9):1992–1999. doi: 10.1038/sj.leu.2404847.
    1. Yañez R., Lamana M. L., García-Castro J., Colmenero I., Ramírez M., Bueren J. A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24(11):2582–2591. doi: 10.1634/stemcells.2006-0228.
    1. Lazarus H. M., Koc O. N., Devine S. M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation. 2005;11(5):389–398. doi: 10.1016/j.bbmt.2005.02.001.
    1. Koç O. N., Gerson S. L., Cooper B. W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Journal of Clinical Oncology. 2000;18(2):307–316.
    1. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet. 2004;363(9419):1439–1441. doi: 10.1016/s0140-6736(04)16104-7.
    1. Ringdén O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81(10):1390–1397. doi: 10.1097/01.tp.0000214462.63943.14.
    1. Fang B., Song Y. P., Liao L. M., Han Q., Zhao R. C. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplantation. 2006;38(5):389–390. doi: 10.1038/sj.bmt.1705457.
    1. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22(3):593–599. doi: 10.1038/sj.leu.2405090.
    1. Krampera M., Sartoris S., Liotta F., et al. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells and Development. 2007;16(5):797–810. doi: 10.1089/scd.2007.0024.
    1. Djouad F., Plence P., Bony C., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102(10):3837–3844. doi: 10.1182/blood-2003-04-1193.
    1. Galiè M., Konstantinidou G., Peroni D., et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene. 2008;27(18):2542–2551. doi: 10.1038/sj.onc.1210920.
    1. Mazzanti B., Aldinucci A., Biagioli T., et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. Journal of Neuroimmunology. 2008;199(1-2):142–150. doi: 10.1016/j.jneuroim.2008.05.006.
    1. Zhao Z. G., Liang Y., Li K., et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells and Development. 2007;16(4):637–648. doi: 10.1089/scd.2007.0008.
    1. Li B., Fu J., Chen P., Zhuang W. Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Archives of Medical Research. 2010;41(8):623–633. doi: 10.1016/j.arcmed.2010.11.008.
    1. Chao Y.-H., Peng C.-T., Harn H.-J., Chan C.-K., Wu K.-H. Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Annals of Hematology. 2010;89(7):715–723. doi: 10.1007/s00277-009-0892-6.
    1. Bacigalupo A., Valle M., Podestà M., et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Experimental Hematology. 2005;33(7):819–827. doi: 10.1016/j.exphem.2005.05.006.
    1. Papadaki H. A., Kritikos H. D., Gemetzi C., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood. 2002;99(5):1610–1619. doi: 10.1182/blood.v99.5.1610.
    1. Kastrinaki M.-C., Sidiropoulos P., Roche S., et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2008;67(6):741–749. doi: 10.1136/ard.2007.076174.
    1. Pérez-Simón J. A., Tabera S., Sarasquete M. E., et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy. 2009;11(6):698–705. doi: 10.3109/14653240903051558.
    1. Nie Y., Lau C., Lie A., Chan G., Mok M. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2010;19(7):850–859. doi: 10.1177/0961203309361482.
    1. Sun L. Y., Zhang H. Y., Feng X. B., Hou Y. Y., Lu L. W., Fan L. M. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121–128. doi: 10.1177/0961203306075793.
    1. Cipriani P., Guiducci S., Miniati I., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis and Rheumatism. 2007;56(6):1994–2004. doi: 10.1002/art.22698.
    1. Shin L., Peterson D. A. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Translational Medicine. 2012;1(2):125–135. doi: 10.5966/sctm.2012-0031.
    1. Kume S., Kato S., Yamagishi S.-I., et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. Journal of Bone and Mineral Research. 2005;20(9):1647–1658. doi: 10.1359/JBMR.050514.
    1. Cramer C., Freisinger E., Jones R. K., et al. Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells and Development. 2010;19(12):1875–1884. doi: 10.1089/scd.2010.0009.
    1. Acosta L., Hmadcha A., Escacena N., et al. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes. 2013;62(12):4266–4269. doi: 10.2337/db13-0896.
    1. Wang B., Wu S.-M., Wang T., et al. Pre-treatment with bone marrow-derived mesenchymal stem cells inhibits systemic intravascular coagulation and attenuates organ dysfunction in lipopolysaccharide-induced disseminated intravascular coagulation rat model. Chinese Medical Journal. 2012;125(10):1753–1759. doi: 10.3760/cma.j.issn.
    1. Moll G., Rasmusson-Duprez I., von Bahr L., et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells. 2012;30(7):1565–1574. doi: 10.1002/stem.1111.
    1. Benvenuti S., Cellai I., Luciani P., et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. Journal of Endocrinological Investigation. 2007;30(9):RC26–RC30. doi: 10.1007/BF03350807.
    1. Lee S., Park J.-R., Seo M.-S., et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Proliferation. 2009;42(6):711–720. doi: 10.1111/j.1365-2184.2009.00633.x.
    1. Moll G., Hult A., von Bahr L., et al. Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS ONE. 2014;9(1) doi: 10.1371/journal.pone.0085040.e85040
    1. Herberts C. A., Kwa M. S. G., Hermsen H. P. H. Risk factors in the development of stem cell therapy. Journal of Translational Medicine. 2011;9, article 29 doi: 10.1186/1479-5876-9-29.
    1. Breitbach M., Bostani T., Roell W., et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362–1369. doi: 10.1182/blood-2006-12-063412.
    1. Kunter U., Rong S., Boor P., et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. Journal of the American Society of Nephrology. 2007;18(6):1754–1764. doi: 10.1681/asn.2007010044.
    1. Wang Y., Huso D. I., Harrington J., et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy. 2005;7(6):509–519. doi: 10.1080/14653240500363216.
    1. Røsland G. V., Svendsen A., Torsvik A., et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 2009;69(13):5331–5339. doi: 10.1158/0008-5472.CAN-08-4630.
    1. Sensebé L., Gadelorge M., Fleury-Cappellesso S. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Research and Therapy. 2013;4(3, article 66) doi: 10.1186/scrt217.
    1. Gálvez P., Clares B., Bermejo M., Hmadcha A., Soria B. Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. Stem Cells and Development. 2014;23(10):1074–1083. doi: 10.1089/scd.2013.0625.
    1. Phinney D. G. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. Journal of Cellular Biochemistry. 2012;113(9):2806–2812. doi: 10.1002/jcb.24166.
    1. Phinney D. G., Kopen G., Righter W., Webster S., Tremain N., Prockop D. J. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. Journal of Cellular Biochemistry. 1999;75(3):424–436.
    1. Ancans J. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Frontiers in Immunology. 2012;3(article 253) doi: 10.3389/fimmu.2012.00253.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner